VivoSim to Carry Forward Organovo 3D Bioprinting
Rhea-AI Summary
Organovo Holdings (Nasdaq: ONVO) has announced its transformation into VivoSim Labs, Inc., marking a strategic evolution of its 3D bioprinting and legacy technology operations. The company's name change will take effect on April 24, 2025, accompanied by a new ticker symbol 'VIVS' on the Nasdaq Capital Market.
The transition requires no action from existing stockholders, and the company will maintain its current CUSIP number (68620A302) and Nasdaq Capital Market listing. This corporate rebranding represents a continuation of Organovo's established bioprinting technology under the new VivoSim identity.
Positive
- Maintains Nasdaq Capital Market listing status
- Continuity of existing 3D bioprinting technology operations
Negative
- None.
News Market Reaction
On the day this news was published, ONVO gained 1.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc.
A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company’s common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol “VIVS” at market open on April 24, 2025.
No action is required by existing stockholders with respect to the name and ticker symbol change. The Company’s common stock will continue to be listed on the Nasdaq Capital Market and the CUSIP number assigned to the Company's common stock (68620A302) will remain unchanged.
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact:
IR@organovo.com
FAQ
When will Organovo (ONVO) change its name to VivoSim Labs and start trading under the new ticker VIVS?
Do Organovo (ONVO) shareholders need to take any action regarding the name and ticker change to VIVS?
What happens to Organovo's 3D bioprinting technology after the transition to VivoSim Labs?
Will the VivoSim Labs (VIVS) stock continue to trade on Nasdaq?
